Circulating Tumor Cell Device Gets Safer FDA Classification
Published Date: 5/6/2026
Rule
Summary
The FDA is officially classifying the circulating tumor cell enrichment device as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to innovative cancer-fighting tools faster and keeps the device safe and effective. The new rules take effect May 6, 2026, and could save time and money for makers and users of this device.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Easier Path for Future Devices
FDA states that once this device type is classified into Class II via the De Novo process, it can serve as a predicate for future devices. That means other device sponsors may be able to use the less-burdensome 510(k) process to bring substantially equivalent devices to market instead of submitting a De Novo request or a premarket approval application.
Device Reclassified to Class II
FDA has classified the circulating tumor cell enrichment device as Class II (special controls). This order is effective May 6, 2026 (and the classification was applicable May 24, 2022). FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access to innovative devices by reducing regulatory burdens.
Manufacturers Must Meet Special Controls
Circulating tumor cell enrichment devices remain subject to premarket notification under section 510(k) and must meet the special controls codified at 21 CFR 866.6110. Manufacturers must provide specified labeling (including intended use, limitations, and troubleshooting) and design verification and validation data, including analytical and clinical study documentation demonstrating performance, detection limits, precision, recovery, and stability.
Labeling Limits Use; Not Diagnostic
The device's labeling must prominently state that the standalone device is intended only to enrich circulating tumor cells (CTCs) from peripheral blood of previously diagnosed cancer patients and is not intended for diagnostic, prognostic, or monitoring use. Labeling must also state that results do not provide information about a patient's current health and that downstream assays need separate validation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
Previous / Next Documents
Previous: 2026-08811, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Preserve and Stabilize Relative Abundances of Microbial Nucleic Acids in Clinical Samples
The FDA is officially putting a special label (Class II) on devices that keep tiny germs’ DNA stable in medical samples. This change makes sure these devices are safe and work well, while also making it easier and faster for new, helpful devices to reach patients. The new rules started May 6, 2026, and could save time and money for companies making these devices.
Next: 2026-08813, Medical Devices; Ophthalmic Devices; Classification of the Corneal Storage Medium With Preservatives Including Antifungals
The FDA is officially putting corneal storage fluids with preservatives and antifungals into a safer, easier-to-manage category called Class II. This change helps make sure these eye care products are safe and effective while speeding up access to new, helpful devices. Starting May 6, 2026, companies will follow these new rules, which could save time and money by cutting down on red tape.